OGFR and cancer: The peptide’s high binding affinity to opioid receptors (Mu/Kappa/Delta types) and low toxicity profile (LD50 > 20 mg/kg, <5% hemolysis at 4 mg/mL) suggests its scaffold could be repurposed for targeting cancer-associated receptors, such as opioid growth factor receptor (OGFR), which is implicated in tumor proliferation and metastasis [242].